5,054 results match your criteria: "Paoli Calmettes Institute; INSERM UMR599 232 Bd[Affiliation]"
Int J Biol Sci
May 2024
Dept. of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid (UCM), Health Research Institute of the "Hospital Clínico San Carlos" (IdISSC), Madrid, Spain.
Chronic cholestatic damage is associated to both accumulation of cytotoxic levels of bile acids and expansion of adult hepatic progenitor cells (HPC) as part of the ductular reaction contributing to the regenerative response. Here, we report a bile acid-specific cytotoxic response in mouse HPC, which is partially impaired by EGF signaling. Additionally, we show that EGF synergizes with bile acids to trigger inflammatory signaling and NLRP3 inflammasome activation in HPC.
View Article and Find Full Text PDFLab Chip
May 2024
Aix-Marseille Université, CNRS, INSERM, CRCM, Institute Paoli-Calmettes, Marseille, France.
display technologies such as yeast display have been instrumental in developing the selection of new antibodies, antibody fragments or nanobodies that bind to a specific target, with affinity towards the target being the main factor that influences selection outcome. However, the roles of mechanical forces are being increasingly recognized as a crucial factor in the regulation and activation of effector cell function. It would thus be of interest to isolate binders behaving optimally under the influence of mechanical forces.
View Article and Find Full Text PDFBull Cancer
June 2024
Institut Paoli-Calmettes, CRCM, Aix-Marseille université, CNRS, Inserm, Marseille, France. Electronic address:
Eur J Haematol
September 2024
Faculte de médecine, INSERM CIC 1402 and U 1313, Centre Hospitalier Universitaire (CHU), Poitiers, France.
Background: IMAGE is a retrospective cohort study of patients enrolled in early access programs (EAPs) in France with relapsed/refractory multiple myeloma (RRMM) receiving isatuximab with pomalidomide and dexamethasone (Isa-Pd).
Methods: Patients aged ≥18 years with RRMM who received ≥1 dose of Isa under the EAPs between July 29, 2019 and August 30, 2020 were included. Effectiveness endpoints included progression-free survival (PFS) and response rates.
Nucleic Acids Res
July 2024
CRCM, CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille 13273, France.
In drug discovery, the successful optimization of an initial hit compound into a lead molecule requires multiple cycles of chemical modification. Consequently, there is a need to efficiently generate synthesizable chemical libraries to navigate the chemical space surrounding the primary hit. To address this need, we introduce ChemoDOTS, an easy-to-use web server for hit-to-lead chemical optimization freely available at https://chemodots.
View Article and Find Full Text PDFTransfus Apher Sci
June 2024
Département d'Hématologie et d'Oncologie Pédiatriques, Hôpital de la Timone-Enfants, Assistance Publique des Hôpitaux de Marseille / Hôpitaux Universitaires de Marseille, Marseille, France.
ESMO Open
May 2024
Association d'enseignement et de recherche des internes en oncologie (AERIO), Paris; Medical Oncology Department, Institut Curie, Versailles Saint-Quentin University, Saint-Cloud.
Iron catalyses the oxidation of lipids in biological membranes and promotes a form of cell death referred to as ferroptosis. Identifying where this chemistry takes place in the cell can inform the design of drugs capable of inducing or inhibiting ferroptosis in various disease-relevant settings. Whereas genetic approaches have revealed underlying mechanisms of lipid peroxide detoxification, small molecules can provide unparalleled spatiotemporal control of the chemistry at work.
View Article and Find Full Text PDFN Engl J Med
April 2024
From the Department of Hematology, Transplant and Cellular Immunotherapy Program, Institut Paoli Calmettes, Management Sport Cancer laboratory, Aix-Marseille University, Marseille, France.
Eur J Cancer
June 2024
Gustave Roussy, Villejuif, France. Electronic address:
Health Qual Life Outcomes
April 2024
Management Sport Cancer Laboratory UR20122035V, Aix Marseille University and Paoli Calmettes Institute, Marseille, France.
Mol Cancer Ther
August 2024
INATHERYS, Evry, France.
J Transl Med
April 2024
Tumor Biology and Immunology Laboratory, Research Branch, Sidra Medicine, Doha, Qatar.
Background: Inflammatory breast cancer (IBC) is the most pro-metastatic form of BC. Better understanding of its enigmatic pathophysiology is crucial. We report here the largest whole-exome sequencing (WES) study of clinical IBC samples.
View Article and Find Full Text PDFLeuk Res
June 2024
Department of Hematology, Institut Paoli-Calmettes, Marseille, France; Aix-Marseille University, INSERM U1068, CNRS, Institut Paoli-Calmettes, CRCM, Marseille, France.
Mutations in spliceosome genes (SRSF2, SF3B1, U2AF1, ZRSR2) correlate with inferior outcomes in patients treated with intensive chemotherapy for Acute Myeloid Leukemia. However, their prognostic impact in patients treated with less intensive protocols is not well known. This study aimed to evaluate the impact of Spliceosome mutations in patients treated with Venetoclax and Azacitidine for newly diagnosed AML.
View Article and Find Full Text PDFFront Immunol
April 2024
Institute for Experimental Cellular Therapy, University Hospital, Essen, Germany.
Optimizing natural killer (NK) cell alloreactivity could further improve outcome after allogeneic hematopoietic cell transplantation (alloHCT). The donor's Killer-cell Immunoglobulin-like Receptor (KIR) genotype may provide important information in this regard. In the past decade, different models have been proposed aiming at maximizing NK cell activation by activating KIR-ligand interactions or minimizing inhibitory KIR-ligand interactions.
View Article and Find Full Text PDFJ Pathol Clin Res
May 2024
Early Oncology Development, Merck & Co., Inc., Rahway, NJ, USA.
The efficacy of pembrolizumab monotherapy versus chemotherapy increased with increasing programmed death ligand 1 (PD-L1) expression, as quantified by combined positive score (CPS; PD-L1 expression on both tumour cells and immune cells) in patients with previously treated metastatic triple-negative breast cancer (mTNBC) in the phase 3 KEYNOTE-119 study. This exploratory analysis was conducted to determine whether the expression of PD-L1 on tumour cells contributes to the predictive value of PD-L1 CPS in mTNBC. PD-L1 expression in tumour samples was assessed using PD-L1 IHC 22C3 pharmDx and quantified using both CPS and tumour proportion score (TPS; PD-L1 expression on tumour cells alone).
View Article and Find Full Text PDFOncoimmunology
April 2024
Molecular Immunology Unit, Biomedical Research Institute Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
T cell-based immunotherapies for solid tumors have not achieved the clinical success observed in hematological malignancies, partially due to the immunosuppressive effect promoted by the tumor microenvironment, where PD-L1 and TGF-β play a pivotal role. However, durable responses to immune checkpoint inhibitors remain limited to a minority of patients, while TGF-β inhibitors have not reached the market yet. Here, we describe a bispecific antibody for dual blockade of PD-L1 and TFG-β, termed AxF (scFv), under the premise that combination with T cell redirecting strategies would improve clinical benefit.
View Article and Find Full Text PDFBackground: This study was a secondary analysis of the ROBOGYN-1004 trial conducted between 2010 and 2015. The study aimed to identify factors that affect postoperative morbidity after either robot-assisted laparoscopy (RL) or conventional laparoscopy (CL) in gynecologic oncology.
Methods: The study used two-level logistic regression analyses to evaluate the prognostic and predictive value of patient, surgery, and center characteristics in predicting severe postoperative morbidity 6 months after surgery.
Eur J Med Chem
May 2024
Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, CEDEX 05, 13385, Marseille, France; AP-HM, Service Central de la Qualité et de l'Information Pharmaceutiques, Hôpital Conception, Marseille, 13005, France.
Cancer is a leading cause of death and a major health problem worldwide. While many effective anticancer agents are available, most drugs currently on the market are not specific, raising issues like the common side effects of chemotherapy. However, recent research hold promises for the development of more efficient and safer anticancer drugs.
View Article and Find Full Text PDFAm J Hematol
July 2024
Univ Brest, Inserm, EFS, UMR 1078, GGB, Brest, France.
Bone Marrow Transplant
July 2024
Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics, National Research Center for Translational Medicine, Blood and Marrow Transplantation Center, Department of Hematology, Collaborative Innovation Center of Hematology, Ruijin Hospital affiliated to School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
While post-transplant cyclophosphamide (PTCy) is commonly used as graft-versus-host disease (GvHD) prophylaxis in haploidentical stem cell transplantation (haplo-HSCT), its dose remains a matter of debate due to side effect concerns. Standard dose of 100 mg/kg associated with tacrolimus and post-engraftment anti-thymocyte globulin (ATG) was used as the reference GvHD prophylaxis in our center and had demonstrated encouraging results. Though PTCy 80 mg/kg was shown to be feasible in patients in reduced-intensity conditioning, whether it exerts equivalent GvHD prophylactic efficacy in myeloablative conditioning (MAC) setting has not been confirmed.
View Article and Find Full Text PDFIntensive Care Med
May 2024
Interdepartmental Division of Critical Care Medicine, Sinai Health System/University Health Network, University of Toronto, Toronto, Canada.
Mol Ther Oncol
March 2024
Centre de Recherches en Cancérologie de Toulouse, CRCT, Université de Toulouse, Inserm, CNRS, Toulouse, France.
Pancreatic cancer will soon become the second cause of death by cancer in Western countries. The main barrier to increase the survival of patients with this disease requires the development of novel and efficient therapeutic strategies that better consider tumor biology. In this context, oncolytic viruses emerge as promising therapeutics.
View Article and Find Full Text PDF